Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines and the risk that the current Phase 2b study of TRU-015 does not help the Company and Wyeth identify a TRU-015 induction dosing regimen or further establish the most effective treatment regimen for TRU-015, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects and such other risks as identified in the company's quarterly report on Form 10-K for the period ended Dec. 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communication

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

<
'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... July 01, 2015 , ... Popular review portal ... navigate. By making fundamental changes to the UI, the website hopes to benefit ... “Finding the right website has been getting tougher. People are seeking professional assistance ...
(Date:6/30/2015)... ... June 30, 2015 , ... Ticket Down is a reputable source of authentic Kid Rock ... Kid Rock, is hitting the road again this summer in what is one of the ... kicked off his summer tour this year at the XFINITY Theatre in Hartford, CT on ...
(Date:6/30/2015)... ... June 30, 2015 , ... Ticket Down is a reliable source for last minute tickets ... has been packing stadiums across North America in conjunction with their 2015 “Zip Code Tour.” ... energy of a band in their twenties. Some of the most beloved songs that ...
(Date:6/30/2015)... ... 2015 , ... According to research by European archeologists that was recently discussed ... four hundred thousand years ago likely knew that eating a balanced diet and limiting ... ancient dental plaque, researchers were able to find evidence of plant fibers, in addition ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... one of Medicare’s top-rated care centers in the country. To spread the word, ... satisfaction and proving its facility is, indeed, worthy of five stars. While Medicare ...
Breaking Medicine News(10 mins):Health News:HerpesDatingSites.org Introduces a New Responsive Design 2Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 2Health News:Recent Article Detailing Research on 400,000 Year Old Dental Plaque Shows Ancestral Understanding of Healthy Eating and Basic Oral Hygiene, Says Feiz Dental 3Health News:Villa Health Care Center Announces Highest Care Rating in New Video 2
... Research Hospital, and Help Kick Off the Fourth Annual ... be Held Monday, Nov. 19 at 11 a.m. at the ... Visitors to Bryant Park on,Monday morning will have the chance ... finishing touches on a three-dimensional canvas mural derived,from a new ...
... National Competition to Raise Radon Awareness, HARRISBURG, ... to national competition after winning the state,s,radon poster ... this,potentially dangerous gas., "I congratulate these students ... aware of radon, and I urge everyone to ...
... ,Green, Design and Operations a Principle Objective for ... ... Nov. 15 Architects and,engineers SMRT Inc. http://www.smrtinc.com/ of ... http://www.gehealthcare.com/ to,design a new digital X-ray detector production facility in ...
... Winston,Laboratories, Inc., a specialty pharmaceutical company engaged ... management, and Getting,Ready Corporation (OTC Bulletin Board: GTRY), ... a merger agreement that will bring,the two companies ... renamed,Winston Pharmaceuticals, Inc., and will be headquartered in ...
... 15 Governor Sonny Perdue today,released a proclamation ... an initiative of the Center for,Health Transformation, founder ... presented at a ceremony honoring the achievement of ... has led to significant,strides toward improving the quality ...
... for Low,Income Subsidies, Enhanced Publications and Online Tools, ... of,Health and Human Services (HHS) announced that, beginning ... enrollment changes in their,health and prescription drug coverage ... Period for prescription drug plan runs from Nov. ...
Cached Medicine News:Health News:American Airlines Invites the Public to Join Marlo Thomas and St. Jude Patients to Create One-of-a-Kind Mural to Celebrate 80 Years of Service in the Greater New York Area 2Health News:American Airlines Invites the Public to Join Marlo Thomas and St. Jude Patients to Create One-of-a-Kind Mural to Celebrate 80 Years of Service in the Greater New York Area 3Health News:American Airlines Invites the Public to Join Marlo Thomas and St. Jude Patients to Create One-of-a-Kind Mural to Celebrate 80 Years of Service in the Greater New York Area 4Health News:PA DEP Secretary Announces Pennsylvania's Radon Poster Contest Winners 2Health News:SMRT Architects and Engineers Selected to Design New $115M Digital X-Ray Manufacturing Facility for GE Healthcare 2Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 2Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 3Health News:Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement 4Health News:Nationally-Recognized Georgia Diabetes Project Honored 2Health News:Nationally-Recognized Georgia Diabetes Project Honored 3Health News:Nationally-Recognized Georgia Diabetes Project Honored 4Health News:2008 Open Enrollment for Medicare Part D Prescription Drug Coverage and Medicare Advantage Plans Begins Today 2Health News:2008 Open Enrollment for Medicare Part D Prescription Drug Coverage and Medicare Advantage Plans Begins Today 3Health News:2008 Open Enrollment for Medicare Part D Prescription Drug Coverage and Medicare Advantage Plans Begins Today 4
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: